Page 3 - காடு ஆய்வகங்கள் இன்க் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Almirall, S.A. (ALM.MC) and Forest Laboratories, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Tudorza(TM) Pressair(TM) (aclidinium bromide inhalation powder) for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.  COPD is a common, progressive, and debilitating lung disease characterized by persistent airflow limitation that makes it hard to breathe; it is currently the third leading cause of mortality in the US. Characteristic symptoms include breathlessness, excessive production of sputum, and a chronic cough. Tudorza(TM) is a twice-daily inhaled long-acting anticholinergic, also referred to as a long-acting muscarinic antagonist (LAMA). Tudorza(TM) produces bronchodilation by inhibiting acetylcholine s effect on muscarinic receptors in the airway smooth muscle. Forest expects Tudorza(TM) Pressair(TM) to be available to wholesalers in the

Howard solomonTudorza pressairJorge gallardoRichard casaburiForest laboratories incGlobal initiative for chronic obstructive lung diseaseDrug administrationForest laboratoriesChief executive officerAssociate chiefCritical care physiologyGlobal initiativeChronic obstructive lung diseaseஹோவர்ட் சாலமன்ஜார்ஜ் கால்டொகாடு ஆய்வகங்கள் இன்க்